With half-year sales of tens of billions of DOLLARs, Coxing Bio responded to entering the real estate: managing rental housing

On January 20, Capital State learned that recently, there was news that the biomedical company SVA. US) set up a new company to enter the real estate industry.

According to Tianyan, Beijing Kexing Yidao Real Estate Co., Ltd. was established on October 13, 2021, with a registered capital of 770 million yuan, the legal representative is Yin Weidong, and the operating status is survival. The business scope includes real estate development and operation; Property management; Operation and management of public parking lots for motor vehicles; Business management, etc.

Beijing Kexing Yidao Real Estate Co., Ltd. is 100% owned by Beijing Kexing Zhongwei Biotechnology Co., Ltd.

In response to this news, Kexing Bio said that Beijing Kexing Yidao Real Estate Co., Ltd. mainly manages rental housing, mainly for employees' housing rental and short-term accommodation of external experts who come to the scene from time to time.

According to the 2021 interim financial report, for the six months ended June 30, 2021, Kexing Bio's sales were US$11 billion, compared with US$67.79 million in the same period last year; Net income attributable to common shareholders was $5.1 billion, compared to a net loss attributable to common shareholders of $12.6 million for the year-ago quarter.

As of the end of December 2021, the company has provided more than 2.5 billion doses of the new crown virus inactivated vaccine CoronaVac® worldwide. The company's annual production capacity of COVID-19 inactivated vaccines exceeds 2 billion doses.

In February 2021, Kexing Bio said on the WeChat public account "Benefits of Vaccines" that the new coronavirus inactivated vaccine Kellyfu ® developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd. ("Kexing Zhongwei"), a subsidiary of Kexing Holding Biotechnology Co., Ltd., has made progress in overseas Phase III clinical trials.

This article originated from Capital State